510(k) K262571
K262571 is an FDA 510(k) premarket notification submitted by Bard Peripheral Vascular, Inc. for the device "EnCor EnCompass Breast Biopsy and Tissue Removal System". The FDA issued a decision of Substantially Equivalent on Aug 14, 2026. The device falls under product code KNW (Instrument, Biopsy), a Class II device regulated under 21 CFR 876.1075. Bard Peripheral Vascular, Inc. has 38 other 510(k) clearances on record.
Clearance details
- Decision
- SESE (Substantially Equivalent)
- Decision Date
- Aug 14, 2026
- Date Received
- Jul 24, 2026
- Clearance Type
- Special
- Expedited Review
- No
- Third Party Review
- No
Device classification
- Device Name
- Instrument, Biopsy
- Device Class
- Class II
- Regulation Number
- 876.1075
- Review Panel
- SU
- Submission Type
- 510(k)